The present invention provides a fully human antibody that binds human EGFRwith affinity comparable to or higher than IMC-C225, and that neutralizesactivation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabsand single chain antibodies, multivalent single chains antibodies, diabodies,triabodies, and single domain antibodies. The invention further providesnucleic acids and host cells and animals that encode and express theseantibodies. The invention further provides a method for neutralizingactivation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or incombination with other agents.